ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Roivant Sciences Ltd. revenue by segment
By business segment
By product or service
| Revenue | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Milestone and Other Revenue [Member] | – | – | – | – | – | – | – | – | $36.77M | $9.62M | $16.47M | $18.68M | – | – |
| Product revenue, net | – | – | – | – | – | – | – | – | $18.37M | $19.31M | $20.67M | $18.42M | – | – |
By region
From the segment and revenue-disaggregation notes of Roivant Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.